THE THREAT OF Pa IN CF INCREASES WITH AGE.1

Pa is the most common chronic infection in patients with cystic fibrosis (CF) and the leading cause of decline in pulmonary function.2

Percentage of CF patients infected with Pa at different age intervals

The burden of Pa is significant

  • Pa infections in CF patients often lead to hospitalization requiring IV antipseudomonal antibiotics3,4
  • In a study, CF patients who became chronically infected with Pa demonstrated an increase in the rate of decline in peak FEV1 percent predicted by 2.1% (P=.004)5
 
Important Safety Information full Prescribing Information www.fda.gov/medwatch

References:

  • Cystic Fibrosis Foundation. Cystic Fibrosis Foundation Patient Registry: 2008 Annual Data Report. Bethesda, MD: Cystic Fibrosis Foundation; 2009.
  • Pamukcu A, Bush A, Buchdahl R. Effects of Pseudomonas aeruginosa colonization on lung function and anthropometric variables in children with cystic fibrosis. Pediatr Pulmonol. 1995;19:10-15.
  • Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med. 1999;340:23-30.
  • Moss RB. Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis. Chest. 2002;121:55-63.
  • McPhail GL, Acton JD, Fenchel MC, Amin RS, Seid M. Improvements in lung function outcomes in children with cystic fibrosis are associated with better nutrition, fewer chronic Pseudomonas aeruginosa infections, and dornase alfa use. J Pediatr. 2008;153:752-757.